Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Arboviral Encephalitis

Arboviral Encephalitis

Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...

Encephalitis l: Introduction

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phage-Encoded Depolymerase DepKP144 with Therapeutic Potential Against Both K1- and K2-Type <i>Klebsiella pneumoniae</i>.

International journal of molecular sciences·2026

Same author

Cloning and Characterization of an Endolysin LysSA120 as a Potential <i>Staphylococcus</i> Biofilm-Removing Agent.

Viruses·2026

Same author

The Podophage PM16 Enhances the Humoral Immune Response Against <i>Proteus mirabilis</i>.

Viruses·2026

Same author

Characterization of the Fiber Protein C-Terminal Domain from <i>Klebsiella pneumoniae</i> Phage KlebP_144 and Evaluation of Its Anti-Capsular Activity.

International journal of molecular sciences·2026

Same author

Phage PM16 Therapy Induce Long-Term Protective Immunity Against <i>Proteus mirabilis</i> via Macrophage Priming.

Pathogens (Basel, Switzerland)·2026

Same author

Molecular Aspects of the Emergence of Monkeypox Virus Clades.

Viruses·2025

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Published on: July 14, 2023

Chimeric antibodies against tick-borne encephalitis virus.

Lev N Levanov¹, Leonid E Matveev, Elena P Goncharova

¹Federal State Research Institution State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region 630559, Russia. levanov.lev@gmail.com

|June 12, 2010

Summary

Two new chimeric antibodies targeting tick-borne encephalitis virus (TBEV) glycoprotein E were developed. The ch13D6 antibody demonstrated effective in vitro neutralization, indicating potential for TBE prophylaxis and therapy.

More Related Videos

Purification of Biotinylated Cell Surface Proteins from Rhipicephalus microplus Epithelial Gut Cells

Purification of Biotinylated Cell Surface Proteins from Rhipicephalus microplus Epithelial Gut Cells

Published on: July 23, 2017

Related Experiment Videos

Last Updated: Jun 12, 2026

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test

Published on: July 14, 2023

Purification of Biotinylated Cell Surface Proteins from Rhipicephalus microplus Epithelial Gut Cells

Purification of Biotinylated Cell Surface Proteins from Rhipicephalus microplus Epithelial Gut Cells

Published on: July 23, 2017

Area of Science:

Immunology
Virology
Biotechnology

Background:

Tick-borne encephalitis virus (TBEV) poses a significant public health threat.
Current therapeutic options for TBE are limited, necessitating the development of novel antiviral strategies.
Monoclonal antibodies (mAbs) are promising candidates for TBE treatment due to their specificity.

Purpose of the Study:

To construct and characterize chimeric antibodies targeting TBEV glycoprotein E.
To evaluate the neutralization capacity of these engineered antibodies against TBEV.
To assess the therapeutic potential of the most effective antibody for tick-borne encephalitis (TBE).

Main Methods:

Variable regions of murine mAbs 13D6 and 10C2 were fused to human constant regions to create chimeric antibodies (ch13D6, ch10C2).
Monovalent single-chain variable fragment (scFv) analogues (sc13D6, sc10C2) were also generated.
Binding characteristics and in vitro neutralization of TBEV infectivity were assessed.

Main Results:

The chimeric antibodies (ch13D6, ch10C2) and scFv analogues (sc13D6, sc10C2) displayed binding similar to their parental murine mAbs.
Only ch13D6 and sc13D6 exhibited significant in vitro neutralization of TBEV.
ch13D6 demonstrated potent neutralization activity against TBEV.

Conclusions:

Engineered chimeric antibodies, particularly ch13D6, retain the binding specificity of their parental mAbs.
ch13D6 shows strong in vitro neutralizing activity against TBEV, highlighting its potential.
Further development of ch13D6 could lead to effective prophylaxis and therapy for tick-borne encephalitis.